Eledon Pharmaceuticals announced that updated results from an investigator-initiated trial of their drug tegoprubart in islet cell transplantation for type 1 diabetes will be presented at the American Diabetes Association 2026 Scientific Sessions. The trial, conducted at the University of Chicago Medicine Transplant Institute, explores tegoprubart's potential to improve graft survival and function by targeting the CD40 Ligand, a key immune system component. This presentation highlights progress in immune-modulating therapies for diabetes, with implications for future treatment options. The session is scheduled for June 7, 2026, in New Orleans.
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
